Gobert A, Lejeune F, Rivet J M, Audinot V, Newman-Tancredi A, Millan M J
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, France.
J Pharmacol Exp Ther. 1995 Jun;273(3):1032-46.
In this study, we used a complementary in vivo electrophysiological and (in individual rats) neurochemical approach to characterize the actions of chemically diverse serotonin (5-HT)1A receptor ligands at central 5-HT1A autoreceptors as compared to dopamine (DA) D2 autoreceptors and presynaptic alpha-2 adrenergic receptors (ARs). The novel, high efficacy, 5-HT1A agonists, WY 48,723 (an arylpiperazine), (+)-flesinoxan (a benzodioxane) and S 14671 and S 14506 (methoxynaphtylpiperazines) mimicked the aminotetralin, 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), in inhibiting the firing of dorsal raphe nucleus (DRN) neurons. Similarly, the firing rate of DRN neurons was reduced by the "partial" agonists, MDL 73005EF, BMY 7378, NAN-190, tandospirone and the novel pyrimidinylpiperazine, zalospirone. Furthermore, S 14489, S 15535 and S 15931, novel benzodioxopiperazines, which behave as antagonists at postsynaptic 5-HT1A receptors, inhibited completely DRN firing, whereas the methoxyphenylpiperazine, WAY 100,135, and the aryloxoarylamine, (-)-tertatolol, were ineffective. Indeed, in analogy to spiperone, both WAY 100,135 and (-)-tertatolol behaved as apparently competitive antagonists in that, in their presence, the dose-response curves for inhibition of DRN firing by S 14671, S 14506 or 8-OH-DPAT were shifted in parallel to the right with no loss of maximal effect. In distinction to WAY 100,135 and (-)-tertatolol, a further novel, putative "antagonist," SDZ 216-525 (a benzoisothiazolpiperazine) weakly inhibited the electrical activity of the DRN. With the exception of (-)-tertatolol, which behaved as a weak agonist, a very similar pattern of inhibition of 5-HT turnover was seen in the striatum (innervated by the DRN), the hippocampus and the hypothalamus (DRN and median raphe nucleus) and the spinal cord (nucleus raphe magnus), with the striatum displaying the greatest sensitivity. Drug potency for inhibition of firing and turnover was highly correlated (r = 0.80-0.82) and these actions were significantly correlated to affinity at (hippocampal) 5-HT1A receptors (r = 0.62-0.73). As concerns DA D2 autoreceptors, the agonist action of apomorphine in reducing DA turnover were mimicked only by 8-OH-DPAT, whereas the majority of the other 5-HT1A ligands, in analogy to raclopride, enhanced DA turnover. The facilitation of DA turnover appeared to reflect direct blockade of DA D2 autoreceptors because potency was correlated powerfully to affinity at these D2 sites (r = 0.89).(ABSTRACT TRUNCATED AT 400 WORDS)
在本研究中,我们采用了一种互补的体内电生理学方法以及(针对个体大鼠的)神经化学方法,来表征化学结构各异的5-羟色胺(5-HT)1A受体配体作用于中枢5-HT1A自身受体的情况,并与多巴胺(DA)D2自身受体及突触前α-2肾上腺素能受体(ARs)进行比较。新型、高效的5-HT1A激动剂WY 48,723(一种芳基哌嗪)、(+)-氟司必林(一种苯并二恶烷)、S 14671和S 14506(甲氧基萘基哌嗪)在抑制中缝背核(DRN)神经元放电方面与氨基四氢萘8-羟基-2-(二正丙基氨基)四氢萘氢溴酸盐(8-OH-DPAT)类似。同样,“部分”激动剂MDL 73005EF、BMY 7378、NAN-190、坦度螺酮以及新型嘧啶基哌嗪扎螺酮也能降低DRN神经元的放电频率。此外,新型苯并二恶哌嗪S 14489、S 15535和S 15931在突触后5-HT1A受体上表现为拮抗剂,它们能完全抑制DRN放电,而甲氧基苯基哌嗪WAY 100,135和芳氧基芳胺(-)-特他洛尔则无效。实际上,与螺哌隆类似,WAY 100,135和(-)-特他洛尔均表现为明显的竞争性拮抗剂,即在此情况下,S 14671、S 14506或8-OH-DPAT抑制DRN放电的剂量反应曲线平行右移,且最大效应未丧失。与WAY 100,135和(-)-特他洛尔不同,另一种新型的假定“拮抗剂”SDZ 216-525(一种苯并异噻唑哌嗪)对DRN的电活动仅有微弱抑制作用。除了表现为弱激动剂的(-)-特他洛尔外,在纹状体(由DRN支配)、海马体、下丘脑(DRN和中缝正中核)以及脊髓(中缝大核)中观察到了非常相似的5-HT周转抑制模式,其中纹状体的敏感性最高。药物抑制放电和周转的效力高度相关(r = 0.80 - 0.82),且这些作用与在(海马体)5-HT1A受体上的亲和力显著相关(r = 0.62 - 0.73)。关于DA D2自身受体,只有8-OH-DPAT能模拟阿扑吗啡降低DA周转的激动剂作用,而其他大多数5-HT1A配体,与雷氯必利类似,能增强DA周转。DA周转的促进作用似乎反映了对DA D2自身受体的直接阻断,因为效力与在这些D2位点的亲和力密切相关(r = 0.89)。(摘要截选至400词)